146 related articles for article (PubMed ID: 22789555)
21. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer--the therapeutic challenge of locally advanced disease.
Blasko JC; Lange PH
N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
[No Abstract] [Full Text] [Related]
23. Prostate cancer with multiple lung metastases in a hemodialysis patient.
Hayakawa K; Matsumoto M; Aoyagi T; Miyaji K; Hata M
Int J Urol; 2000 Dec; 7(12):464-6. PubMed ID: 11168686
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT imaging in prostate adenocarcinoma presenting as isolated brain metastases of unknown origin.
Erhamamcı S; Reyhan M; Alkan O
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):146-7. PubMed ID: 25052407
[No Abstract] [Full Text] [Related]
25. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
26. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.
Souhami L; Bae K; Pilepich M; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1301-6. PubMed ID: 20356687
[TBL] [Abstract][Full Text] [Related]
27. [Brain metastasis of prostatic cancer: regression under hormonal treatment].
Ameur A; Touiti D; el Mostarchid B; el Alami M; Jira H; Abbar M
Prog Urol; 2001 Dec; 11(6):1298-301. PubMed ID: 11859670
[TBL] [Abstract][Full Text] [Related]
28. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
29. Penile metastases from carcinoma of the prostate.
Pandian SS; McGuire M; McClinton S; Kerr KM
Br J Urol; 1997 May; 79(5):807. PubMed ID: 9158527
[No Abstract] [Full Text] [Related]
30. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
31. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
32. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review.
Sasse AD; Sasse E; Carvalho AM; Macedo LT
BMC Cancer; 2012 Feb; 12():54. PubMed ID: 22299707
[TBL] [Abstract][Full Text] [Related]
33. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
34. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
35. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
36. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
[TBL] [Abstract][Full Text] [Related]
37. The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
Chao D; Harland SJ
Eur Urol; 1997; 31(1):7-10. PubMed ID: 9032527
[TBL] [Abstract][Full Text] [Related]
38. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.
Kaufman DS; McDougal WS; Zietman AL; Harisinghani MG; Young RH
N Engl J Med; 2004 Jul; 351(2):171-8. PubMed ID: 15247358
[No Abstract] [Full Text] [Related]
39. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
Souhami L; Bae K; Pilepich M; Sandler H
J Clin Oncol; 2009 May; 27(13):2137-43. PubMed ID: 19307511
[TBL] [Abstract][Full Text] [Related]
40. Treatment of prostate cancer with goserelin and radiotherapy.
Vicini FA; Kini VR; Martinez AA
N Engl J Med; 1997 Dec; 337(23):1693-4. PubMed ID: 9411236
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]